Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.
Aged
Androstadienes
/ administration & dosage
Breast Neoplasms
/ drug therapy
Cyclophosphamide
/ administration & dosage
Docetaxel
/ administration & dosage
Drug Administration Schedule
Female
Humans
Middle Aged
Neoadjuvant Therapy
Receptors, Estrogen
/ metabolism
Survival Analysis
Treatment Outcome
Tumor Burden
/ drug effects
Ki67 labeling index
aromatase inhibitors
breast neoplasms
docetaxel and cyclophosphamide
tailored therapy
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
19
03
2019
revised:
28
06
2019
accepted:
03
07
2019
pubmed:
31
7
2019
medline:
22
8
2020
entrez:
31
7
2019
Statut:
ppublish
Résumé
Our aim was to investigate the efficacy and safety of initial neoadjuvant endocrine therapy with exemestane alone followed by tailored treatment, either continued exemestane monotherapy or exemestane plus docetaxel-cyclophosphamide (TC) combination therapy, in postmenopausal patients with primary invasive estrogen receptor-positive, human epidermal growth factor receptor 2-negative, stage I-IIIA breast cancer and Ki67 labeling index ≤30%. In this open-label phase II study, patients initially received exemestane 25 mg/d for 12 weeks. Responders were defined as patients who achieved complete response (CR), partial response (PR) with Ki67 labeling index ≤5% after treatment, or stable disease with Ki67 labeling index ≤5% both before and after treatment. For the subsequent 12 weeks, exemestane monotherapy was continued for responders (group A), whereas nonresponders received exemestane plus four cycles of TC (docetaxel 75 mg/m
Identifiants
pubmed: 31361400
doi: 10.1002/cam4.2423
pmc: PMC6745863
doi:
Substances chimiques
Androstadienes
0
Receptors, Estrogen
0
Docetaxel
15H5577CQD
Cyclophosphamide
8N3DW7272P
exemestane
NY22HMQ4BX
Types de publication
Clinical Trial, Phase II
Comparative Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
5468-5481Subventions
Organisme : Japan Breast Cancer Research Group
Informations de copyright
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Cancer Med. 2019 Sep;8(12):5468-5481
pubmed: 31361400
J Clin Oncol. 2017 Apr 1;35(10):1061-1069
pubmed: 28045625
Acad Radiol. 1997 Jan;4(1):8-12
pubmed: 9040864
J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64
pubmed: 21960707
Cancer Med. 2018 Sep;7(9):4467-4474
pubmed: 30123969
J Clin Oncol. 2009 Mar 10;27(8):1177-83
pubmed: 19204201
Oncol Lett. 2019 Jan;17(1):616-622
pubmed: 30655808
PLoS One. 2012;7(5):e37379
pubmed: 22662150
Arch Surg. 1982 Jul;117(7):879-81
pubmed: 7092538
J Clin Oncol. 2007 Sep 1;25(25):3808-15
pubmed: 17664460
Rev Recent Clin Trials. 2017;12(2):67-72
pubmed: 28155606
JAMA Oncol. 2016 Nov 1;2(11):1477-1486
pubmed: 27367583
Breast. 2008 Aug;17(4):323-34
pubmed: 18455396
J Am Coll Surg. 2009 May;208(5):906-14; discussion 915-6
pubmed: 19476859
Breast. 2015 Nov;24 Suppl 2:S67-72
pubmed: 26283598
Chin Clin Oncol. 2015 Sep;4(3):34
pubmed: 26408301
J Clin Oncol. 1997 Jul;15(7):2483-93
pubmed: 9215816
J Clin Oncol. 2006 Dec 1;24(34):5381-7
pubmed: 17135639
ANZ J Surg. 2006 Nov;76(11):1002-6
pubmed: 17054550
Pathology. 2017 Feb;49(2):166-171
pubmed: 28065411
Ann Oncol. 2006 Jan;17(1):85-92
pubmed: 16251204
Urol Oncol. 2017 Aug;35(8):499-506
pubmed: 28648414
J Natl Cancer Inst. 1986 Feb;76(2):171-8
pubmed: 3456058
Cancer Med. 2018 Jun 14;:
pubmed: 29905023
J Natl Cancer Inst. 2007 Jan 17;99(2):167-70
pubmed: 17228000
Br J Cancer. 2007 May 21;96(10):1504-13
pubmed: 17453008
Pathol Res Pract. 2019 Jan;215(1):29-33
pubmed: 30501932
Breast Cancer Res Treat. 2013 Jun;139(2):539-52
pubmed: 23674192
Cancer Sci. 2011 Apr;102(4):858-65
pubmed: 21231986
J Clin Oncol. 2008 Dec 1;26(34):5569-75
pubmed: 18981464
J Clin Oncol. 2007 Sep 1;25(25):3871-6
pubmed: 17664457
Br J Cancer. 2006 Apr 10;94(7):1051-6
pubmed: 16538221
Cancer Discov. 2017 Jun;7(6):561-574
pubmed: 28495849
Curr Breast Cancer Rep. 2017;9(4):202-209
pubmed: 29201277